

1 **Title: Respi-Radar – a tool to monitor respiratory infections in Belgium during the winter season 2023-**  
2 **2024**

3 **Authors:** Géraldine De Muylder<sup>1</sup>; Simon Couvreur<sup>1</sup>, Giulietta Stefani<sup>1</sup>, Claire Brugerolles<sup>1</sup>, Yinthe Dockx<sup>1</sup>,  
4 Milena Callies<sup>2</sup>, Raphaël Janssens<sup>1</sup>, Laurane De Mot<sup>1</sup>, Nathalie Bossuyt<sup>1</sup> and Jorgen Stassijns<sup>3</sup>

5 **Affiliations:** 1. Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium; 2. Healthcare associated  
6 infections and antimicrobial resistance, Sciensano, Brussels, Belgium; 3. Crisis Coordination, Sciensano,  
7 Brussels, Belgium

8 **Abstract**

9 Following the experience gathered during the COVID-19 crisis, the Respi-Radar was developed by the  
10 Belgian Risk Assessment Group (RAG) in the summer of 2023, with the aim of assessing the  
11 epidemiological situation of respiratory infections and informing public health preparedness and response  
12 in Belgium.

13 The Respi-Radar consisted of four levels (green, yellow, orange and red) which indicated the extent of  
14 viral circulation and/or pressure on the healthcare system. Depending on the level, specific measures  
15 would apply to reverse the trend. The Respi-Radar used six indicators, from the Influenza-Like Illness and  
16 Severe Acute Respiratory Infection sentinel surveillances in nursing homes, primary and secondary care,  
17 as well as from the wastewater surveillance. Additional information, such as data from the national  
18 reference laboratories, also contributed to assessing the situation.

19 Based on the Respi-Radar tool, the RAG regularly evaluated the epidemiological situation of respiratory  
20 infections between September 2023 and March 2024.

21 The Respi-Radar tool appeared useful for following trends and effectively communicating on the  
22 epidemiological situation of respiratory infections. Applying specific measures depending on a level was  
23 less straightforward. The experience gained using the Respi-Radar tool was key to determine the best  
24 approach to assess and manage the epidemiological situation for future respiratory seasons.

25

## 26           **1- Introduction**

27       In Belgium, as in other countries, the COVID-19 crisis led to the enhancement of existing surveillance  
28       systems and to the development of novel structures resulting in unprecedented amounts and types of  
29       data available. So called “management tools” were created to carry out an evaluation of the  
30       epidemiological situation of COVID-19, on a regular basis and in a structured way. The tools incorporated  
31       key indicators and thresholds to define risk levels, which would ultimately offer guidance to policy makers  
32       (1).

33       These tools, developed by the Risk Assessment Group (RAG, a scientific expert group coordinated by the  
34       Belgian Institute of Health, Sciensano (2)) were successively used for COVID-19 between September 2020  
35       and August 2023, as already described (1). The last COVID-19 management tool, from December 2021,  
36       distinguished three levels: Epidemiological situation under control (Level 1), Increasing viral circulation  
37       potentially leading to pressure on the health care system (Level 2), and High viral circulation with possible  
38       health care system overload (Level 3). The levels were based on several indicators, essentially reflecting  
39       the COVID-19-related pressure on the healthcare system (number of hospital admissions due to COVID-  
40       19, COVID-19-related intensive care unit (ICU) occupancy and number of consultations of general  
41       practitioners (GP) for suspicion of COVID-19), as well as other indicators such as positivity rate for  
42       symptomatic patients, reproductive number (Rt) and 14-day incidence of cases.

43       In the context of co-circulation of SARS-CoV-2 and other respiratory pathogens, it became necessary to  
44       develop a management tool that would take into account not only SARS-CoV-2 but also other respiratory  
45       pathogens. The “Respi-Radar” tool was introduced in the summer 2023, with the aim of assessing the  
46       epidemiological situation of all major respiratory infections and informing public health preparedness and  
47       response.

48       This document first describes the Respi-Radar tool, its implementation and how it was used during the  
49       2023-2024 respiratory season. It then presents a brief evaluation of the tool and discusses its advantages  
50       and drawbacks.

51

## 52           **2- Description of the Respi-Radar tool**

### 53                   a. *Indicators used*

54       The Respi-Radar was based on five pathogen-agnostic indicators from sentinel surveillance systems of  
55       respiratory infections, as well as one COVID-19-specific indicator. These indicators allowed for monitoring  
56       the circulation of respiratory pathogens, the severity of diseases and their impact on the healthcare  
57       system. They are listed in Table 1.

58

59 **Table 1 Indicators used in the Respi-Radar**

Indicators	Source	Reference
Weekly incidence of consultations of general practitioners (GPs) for influenza-like illness (ILI), per 100,000 inhabitants	Sentinel network of GPs	(8)
Weekly incidence of consultations of GPs for other Acute Respiratory Infections (ARI), per 100,000 inhabitants	Sentinel network of GPs	(8)
Weekly incidence of ILI cases in nursing homes, per 1,000 nursing home residents	Sentinel network of nursing homes	(9)
Weekly incidence of hospitalization for Severe Acute Respiratory Infections (SARI), per 100,000 inhabitants	Sentinel network of hospitals	(8)
Weekly incidence of SARI hospitalization with severe complications (invasive ventilation, ECMO, admission to intensive care, Acute Respiratory Distress Syndrome, death), per 100,000 inhabitants	Sentinel network of hospitals	(8)
number of wastewater treatment plants with high concentrations of SARS-CoV-2	Wastewater surveillance	(10)

60

61 *b. Definition of thresholds*

62 Different thresholds were defined for each indicator. For the incidence of GP consultations for Influenza-  
 63 Like Illness (ILI), the incidence of GP consultations for Acute Respiratory Infections (ARI) and the incidence  
 64 of hospital admissions for Severe Acute Respiratory Infections (SARI), the levels were defined by the  
 65 Moving Epidemic Method (MEM), with support from ECDC for ILI. The MEM uses historical data from past  
 66 epidemic waves to identify potential upcoming epidemics and assess their intensity (4). For the incidence  
 67 of ILI cases in nursing homes and the number of wastewater treatment plants with a high concentration  
 68 of SARS-CoV-2, the historical data were insufficient to use the MEM. Thresholds were therefore set by  
 69 experts, by consensus. All thresholds are summarized in Table 2.

70

71 **Table 2 Risk levels in the Respi-Radar and thresholds defined for each indicator**

Risk level	Consultations GPs for ILI*	Consultations GPs for ARI*	ILI in nursing homes**	Hospitalisations for SARI*	Severity SARI***	SARS-CoV-2 wastewater****
Green	<128	<1208	<7	<4,4	<0,68	<5
Yellow	128-507	1208-1293	7-13	4,4-9,8	0,68 - 1,4	5 – 10 stations +
Orange	508-783	1294-1984	14-20	9,9-33,7	1,41 - 3,03	11-15 stations +
Red	>783	>1984	>20	>33,7	> 3,03	> 15 stations +

72 \* weekly incidence per 100,000 inhabitants

73 \*\* weekly incidence per 1,000 nursing home residents

74 \*\*\* weekly incidence per 100,000 inhabitants. A complication is defined as death, ARDS, admission to  
 75 ICU, ECMO or invasive ventilation.

76 \*\*\*\* Number of treatment plants with high concentrations of SARS-CoV-2 as defined in (10)

77

78 *c. Definition of Respi-Radar levels*

79 The Respi-Radar was divided into four levels (Table 2). The green level was the baseline and reflected a  
80 non-epidemic situation. The yellow level represented a situation where the epidemic threshold was  
81 passed for some indicators, pathogens were circulating, but the impact on the healthcare system  
82 remained limited. The orange level was characterized by a moderate pathogen circulation, which exerted  
83 some pressure on the healthcare system. The red level reflected a situation where pathogen circulation  
84 was high, with an important risk of healthcare system overload. The thresholds set for each indicator  
85 determined the Respi-Radar levels.

86 *d. Functioning of the Respi-Radar*

87 Data from the surveillance of respiratory infections were available once a week and compiled in the  
88 weekly bulletin of acute respiratory infections (3).

89 Every week, the experts of the RAG analyzed the indicators defining the Respi-Radar and estimated an  
90 overall risk level which characterized the epidemiological situation for the week under review. The  
91 assessment was based on the indicators of the Respi-Radar but other relevant information could also be  
92 included when needed, for instance the European (through ERVISS (4)) and international situation,  
93 genomic surveillance data or qualitative information provided by the experts of the group. In addition to  
94 estimating the risk level, the RAG could propose appropriate actions, such as emphasizing the importance  
95 of vaccination and basic protective measures or reinforcing communication with relevant groups.

96 The risk level and actions proposed by the RAG were then presented weekly to the Risk Management  
97 Group (RMG, composed of representatives of health authorities -administration and ministries- and  
98 coordinated by the ministry of health), which validated the analysis and decided on measures to be  
99 applied (5). Specific sets of measures adapted to each risk level of the Respi-Radar were developed by  
100 various advisory bodies (6).

101 **3- Use of the Respi-Radar tool during the respiratory season 2023-2024**

102 Table 3 shows the levels of the indicators by week as well as the assessment made by the RAG, between  
103 July 2023 (week 29) and March 2024 (week 13). The epidemiological situation for respiratory infections  
104 was assessed as being at baseline (risk level *green*) between July and mid-November 2023 (weeks 29 to  
105 45). From November 23, 2023 (week 46) to January 21, 2024 (week 3), the situation was assessed as being  
106 at risk level *yellow*, because several indicators showed increasing trends. Nevertheless, the situation was  
107 under control with a limited impact on healthcare (first and second line). The increase was due to a rise  
108 in RSV circulation in October, followed by increased SARS-CoV-2 circulation in December. From January  
109 22, 2024 (week 4) to February 18, 2024 (week 7), the epidemiological situation for respiratory infections  
110 was at risk level *orange*, mainly due to the increased circulation of Influenza and the subsequent pressure  
111 on healthcare. The epidemiological situation was assessed as being at risk level *yellow* again on February  
112 19, 2024 (week 8), because the impact on the healthcare system was limited, despite viral circulation  
113 above the epidemic threshold,. From March 11, 2024 (week 11) and until the end of the respiratory  
114 season, the epidemiological situation for respiratory infections remained at baseline.

115 In accordance with the estimated risk level, the RAG proposed several actions over time. In September  
 116 2023, the risk level was *green*, but in light of the upcoming respiratory season, the RAG recommended  
 117 that the existing guidelines for managing cases of COVID-19 and respiratory infections in general would  
 118 be repeated. In October 2023, still at risk level *green*, the RAG stressed the importance of maintaining  
 119 basic protective measures (washing hands, staying at home or wearing a mask in case of symptoms). The  
 120 RAG also emphasized the importance of vaccination against respiratory pathogens (Influenza, SARS-CoV-  
 121 2, RSV and pneumococcus) for vulnerable populations. In November 2023, when the risk level was  
 122 increased to *yellow*, the RAG referred to the recommendations formulated by other advisory bodies for  
 123 the general population in Belgium: stay at home in case of symptoms, ventilate indoor spaces, wear a  
 124 mask in case of symptoms, and vaccinate at-risk populations against respiratory pathogens.  
 125 Recommendations for the healthcare sector were proposed by the RMG. In January 2024, when the risk  
 126 level was raised to *orange*, no additional measures were set, but the RMG reinforced communication  
 127 towards the public and the healthcare sector to reiterate the measures described above and stress the  
 128 importance of ventilation and protection of vulnerable people.

129

130 **Table 3 Respi Radar evaluation July 2023 – March 2024**

Week	Indicators acute respiratory infections					COVID-19 specific indicator	Evaluation RAG
	Consultations GPs for ILI symptoms*	Consultations GPs for ARI *	ILI in nursing homes **	Hospital admissions for SARI*	SARI hospitalizations with severe complications** *	Concentration SARS-CoV-2 in wastewater****	
2023w29	30	353	3	1,3	0,5	0	green
2023w30	37	401	3	2,3	0,1	0	green
2023w31	59	419	3	2,9	0,7	3	green
2023w32	29	387	2	2	0,3	7	green
2023w33	79	383	3	3,9	0,6	5	green
2023w34	87	447	5	5,1	0,7	8	green
2023w35	82	526	7	6,1	0,5	10	green
2023w36	150	667	6	6,4	0	14	green
2023w37	138	650	4	4,9	0	7	green
2023w38	142	774	5	6,2	0	9	green
2023w39	181	994	8	8,2	0,4	14	green
2023w40	149	1105	7	6,6	0,4	10	green
2023w41	153	1074	4	6,7	0,3	15	green
2023w42	159	1129	6	8,5	0,4	11	green
2023w43	68	938	7	7,3	1,2	8	green
2023w44	159	906	8	11,3	0,7	9	green
2023w45	191	1367	5	12,1	0,3	10	green
2023w46	184	1087	13	11,1	2,7	14	yellow
2023w47	225	1169	10	12,7	1,8	19	yellow
2023w48	242	1330	11	13,6	1,3	20	yellow

2023w49	259	1487	15	12,6	2,2	24	yellow
2023w50	399	1426	5	12,6	2,2	22	yellow
2023w51	450	1518	9	16,7	1,3	27	yellow
2023w52	167	1212	8	14,5	1,4	19	yellow
2024w01	216	971	11	15,4	1,8	11	yellow
2024w02	298	1059	13	13,9	2	11	yellow
2024w03	325	1200	13	11,2	1,4	13	yellow
2024w04	636	1444	11	12,5	2,7	11	orange
2024w05	588	1623	12	12,9	1,0	9	orange
2024w06	557	1252	16	14,8	1,5	3	orange
2024w07	289	1061	7	15,9	1,5	4	orange
2024w08	333	1205	6	11,6	0,7	6	yellow
2024w09	228	921	8	11,5	0,9	4	yellow
2024w10	127	975	7	9,1	0,6	1	yellow
2024w11	153	813	8	9,2	1,5	2	green
2024w12	76	865	4	9,9	0,9	0	green
2024w13	95	940	3	8,4	1,1	0	green

131

132

#### 4- Evaluation of the Respi-Radar

133

134

135

136

137

138

In the spring of 2024, the RAG conducted an evaluation of the Respi-Radar which included the analysis of the relevance and sensitivity of the chosen indicators, the timely availability of data, the adequacy of the thresholds and the actions taken. The evaluation was based on two components: (i) an analysis of the evolution of each indicator monitored within the Respi-Radar during the 2023-2024 season and their alignment with the global level defined each week, and (ii) a survey carried out among the experts participating to the RAG.

139

##### *a. Analysis of the indicators of the Respi-Radar*

140

141

142

First, the completeness of the data available for the Respi-Radar evaluation was assessed for each indicator by comparing the data available at the time of the evaluation and the data when consolidated (Figure 1).

143

144

145

146

147

148

149

150

151

152

Data from the sentinel networks of GPs and nursing homes were slightly underestimated or overestimated on the day of the Respi-Radar evaluation, with stronger underestimation at epidemiological peaks (Figure 1A, 1B and 1C). The trends were however correctly captured on the day of the evaluation. The incidence of hospital admissions for SARI (from the sentinel network of hospitals) was considerably underestimated between November and December 2023 due to several changes in the surveillance system (expansion of the sentinel network, change in the data collection system). From January 2024 onwards, the situation greatly improved and reflected the trends observed in data from the sentinel network of GPs (Figure 1D). On the other hand, the incidence of SARI hospitalizations with severe complications, collected from the network of hospitals, was never available at the time of the Respi-Radar evaluation. This indicator being collected at patient discharge, typically required four to five weeks to be consolidated (Figure 1E). The

153 number of wastewater treatment plants positive for SARS-CoV-2 was always available at the time of the  
154 Respi-Radar evaluation (Figure 1F).

155 The evolution of each individual indicator was examined in parallel to the overall risk levels attributed  
156 over time through the Respi-Radar (Figure 1).

157 For four indicators of the Respi-Radar (incidence of consultations at GP practices for ILI symptoms;  
158 incidence of consultations at GP practices for ARI; incidence of hospital admissions for SARI and incidence  
159 of ILI in nursing homes), the evolution taken individually matched the Respi-Radar overall evaluation:  
160 increasing trends were observed when the risk level was changed from *green* to *yellow* then from *yellow*  
161 to *orange*. Conversely, the trend was decreasing when the risk level of the Respi-Radar changed from  
162 *orange* to *yellow* then from *yellow* to *green*. The incidence of complications after hospitalisations for SARI  
163 was not available at the time of Respi-Radar analysis, but consolidated data showed a good match with  
164 the overall Respi-Radar evaluation.

165 The indicator on viral concentrations in wastewater did not match the Respi-Radar evaluation, as, during  
166 the period considered here (July 2023-March 2024), this indicator remained pathogen-specific, with only  
167 SARS-CoV-2 concentrations measured in wastewater while the Respi-Radar evaluated respiratory  
168 infections in general.

169

#### 170 *b. Feedback from the experts of the RAG*

171 A survey was sent to the RAG experts in April 2024, asking them for feedback on the selection of indicators  
172 within the Respi-Radar, the epidemiological thresholds defined for these indicators, the correspondence  
173 between the Respi-Radar level and the epidemiological situation, as well as the usefulness of the Respi-  
174 Radar as a decision supporting tool.

175 The participation rate was 69 % (18/26). The indicators and thresholds chosen were generally considered  
176 adequate, with the exception of the incidence of severe complications after hospitalization for SARI, for  
177 which the delay was considered too long to obtain reliable data. The Respi-Radar was seen by the experts  
178 as a useful tool for monitoring trends of respiratory infections in a standardized manner, and for clear  
179 communication of the epidemiological situation to the authorities, the healthcare sector and the general  
180 public. However, applying a pre-defined set of measures to each determined risk level was challenging,  
181 so the decision-supporting aspect of the tool was less recognized.

182

## 183 **5- Conclusion**

184 The Respi-Radar was implemented at the end of summer 2023, and was used during the autumn-winter  
185 2023-2024 season in Belgium. This season was characterized by an influenza epidemic of moderate  
186 intensity and relatively long duration (11 weeks), a COVID-19 peak with limited impact in December 2023,  
187 and an RSV peak in October 2023 which intensity was comparable to the previous year. No measures were  
188 imposed by the authorities on the healthcare sector or the population, but recommendations were  
189 formulated.

190 The Respi-Radar was built from management tools developed during the COVID-19 crisis to inform and  
191 guide political decisions. It aimed at providing an integrated evaluation of the epidemiological situation,  
192 taking into account respiratory infections in general, and ensuring a system for early warning.

193 This unique system in Europe allowed for a standardized evaluation of the epidemiological situation of  
194 respiratory infections in Belgium and therefore facilitated communication to authorities, the healthcare  
195 sector and even the general population.

196 The Respi-Radar could be of significant interest to international public health organizations and other  
197 countries due to its alignment with the recommendations from the ECDC on respiratory virus surveillance  
198 (7). The tool aligns with the ECDC's call for strengthening surveillance during non-pandemic periods,  
199 ensuring responsiveness to emerging viruses and monitoring of multiple respiratory viruses. It also  
200 includes both epidemiological and virological data to understand the intensity, spread, and characteristics  
201 of viruses. Due to its flexibility, the method could be adopted by countries with differing healthcare  
202 infrastructures and surveillance capacities, aiding in building a more resilient international surveillance  
203 network.

204 A limitation, however, is the use of thresholds, which are based on historical data from each surveillance  
205 system. In some cases, these data may be incomplete, or system changes may create inconsistencies.  
206 Furthermore, thresholds that are effective during non-pandemic periods may not be as useful during  
207 pandemics. Even in syndromic surveillance, the introduction of a new pathogen and disruptions to the  
208 seasonality of known pathogens can result in unusually high peaks, complicating the detection of changing  
209 risks. Therefore, thresholds should be interpreted with caution, requiring expert judgment.

210 In line with the conclusions drawn during the review of the management tools previously developed for  
211 COVID-19 (1), challenges remain to link predefined sets of recommendations to the specific risk levels of  
212 the Respi-Radar tool.

213 The Respi-Radar will be used in the coming respiratory seasons in Belgium. Adaptations are foreseen to  
214 improve the detection and monitoring of respiratory infections, but also to establish risk level-based  
215 sets of measures. These measures should be implemented in a timely manner to help mitigate and  
216 control pressure on the healthcare system.

217

## 218 **6- Acknowledgements**

219 The authors sincerely thank the members of the Risk Assessment Group who provided advice and  
220 expertise on a regular basis and constitute an essential pillar of this work. The authors also thank all  
221 participants to the sentinel surveillances in place in Belgium.

222



223 **7- References**

- 224 1. De Muylder G, Laisnez V, Stefani G, Boulouffe C, Faes C, Hammami N, et al. Translating the  
225 COVID-19 epidemiological situation into policies and measures: the Belgian experience. *Front Public*  
226 *Health* [Internet]. 2024 Apr 5 [cited 2024 Sep 3];12. Available from:  
227 <https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1306361/full>
- 228 2. SPF Santé publique [Internet]. 2019 [cited 2023 May 24]. Protocole d'accord entre les autorités  
229 sanitaires belges. Available from: <https://www.health.belgium.be/fr/protocole-daccord-entre-les->  
230 [autorites-sanitaires-belges](https://www.health.belgium.be/fr/protocole-daccord-entre-les-)
- 231 3. Brugerolles. *sciensano.be*. Sciensano; 2024 [cited 2024 Nov 8]. Bulletin infections respiratoires  
232 aiguës semaine 44-2024 - Publié 06/11/24. Available from: <https://www.sciensano.be/fr/biblio/bulletin->  
233 [infections-respiratoires-aigues-semaine-44-2024-publie-06-11-24](https://www.sciensano.be/fr/biblio/bulletin-)
- 234 4. European Centre for Disease Prevention and Control , World Health Organization Regional Office  
235 for Europe. *European Respiratory Virus Surveillance Summary (ERVISS)*, Stockholm and Copenhagen:  
236 ECDC and WHO/Europe. Available from: <https://erviss.org>.
- 237 5. FPS Public Health [Internet]. 2023 [cited 2024 Sep 24]. Risk Management Group (RMG).  
238 Available from: <https://www.health.belgium.be/en/risk-management-group-rmg>
- 239 6. SPF Santé publique [Internet]. 2023 [cited 2023 Dec 11]. Strategy Scientific Committee (SSC).  
240 Available from: <https://www.health.belgium.be/fr/strategy-scientific-committee-ssc>
- 241 7. Operational considerations for respiratory virus surveillance in Europe [Internet]. 2022 [cited  
242 2023 Sep 25]. Available from: <https://www.ecdc.europa.eu/en/publications-data/operational->  
243 [considerations-respiratory-virus-surveillance-europe](https://www.ecdc.europa.eu/en/publications-data/operational-)
- 244 8. *sciensano.be* [Internet]. [cited 2023 Jan 26]. Sciensano & Acute respiratory tract infection.  
245 Available from: <https://www.sciensano.be/en/health-topics/acute-respiratory-tract-infection/role>
- 246 9. *sciensano.be* [Internet]. [cited 2023 Dec 11]. Surveillance-sentinelle des syndromes grippaux (y  
247 compris COVID-19) dans les maisons de repos (et de soins) belges. Available from:  
248 <https://www.sciensano.be/fr/projets/surveillance-sentinelle-des-syndromes-grippaux-y-compris-covid->  
249 [19-dans-les-maisons-de-repos-et-de](https://www.sciensano.be/fr/projets/surveillance-sentinelle-des-syndromes-grippaux-y-compris-covid-)
- 250 10. Janssens R, Hanoteaux S, Maloux H, Klamer S, Laisnez V, Verhaegen B, et al. SARS-CoV-2  
251 Surveillance in Belgian Wastewaters. *Viruses*. 2022 Sep 2;14(9):1950.

252

253

254 **Figure 1 Analysis of the indicators used in the Respi-Radar**

255 Data available at the time of the Respi Radar analysis (orange line) were compared to the same data when  
256 consolidated (blue line) from week 34 2023 to week 13 2024. Colored boxes (green, yellow or orange)  
257 indicate the overall risk level defined weekly through the Respi-Radar. A- Weekly incidence of  
258 consultations at GP practices for ILI symptoms; B- Weekly incidence of consultations at GP practices for  
259 ARI; C- Weekly incidence of ILI in nursing homes; D- Weekly incidence of hospital admissions for SARI; E-  
260 Weekly incidence of SARI hospitalizations with severe complications; F- Number of treatment plants with  
261 high concentrations of SARS-CoV-2.

262

Figure 1

